DND PharmaTech Inc banner
D

DND PharmaTech Inc
KOSDAQ:347850

Watchlist Manager
DND PharmaTech Inc
KOSDAQ:347850
Watchlist
Price: 92 300 KRW 15.38% Market Closed
Market Cap: ₩4T

Relative Value

The Relative Value of one DND PharmaTech Inc stock under the Base Case scenario is 3 699.67 KRW. Compared to the current market price of 92 300 KRW, DND PharmaTech Inc is Overvalued by 96%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
3 699.67 KRW
Overvaluation 96%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
DND PharmaTech Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
KR
DND PharmaTech Inc
KOSDAQ:347850
4T KRW 479.3 -115.3 -116.6 -100.2
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 690 872.8 -160 127.7 -194 446.1 -192 227.3
US
Abbvie Inc
NYSE:ABBV
388.4B USD 6.4 92.8 15.3 21.2
US
Amgen Inc
NASDAQ:AMGN
197.4B USD 5.4 25.6 14.7 14.7
US
Gilead Sciences Inc
NASDAQ:GILD
179.9B USD 6.1 21.2 13.2 16.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.2B USD 9.9 30.2 22.7 23.7
US
Epizyme Inc
F:EPE
94.1B EUR 2 091 -533.6 -581 -565.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.8B USD 5.5 17.5 12.9 14.8
AU
CSL Ltd
ASX:CSL
68B AUD 3.1 34.5 11.4 14.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.8 -66.6 -60.1
NL
argenx SE
XBRU:ARGX
37.8B EUR 10.6 34 36.8 37.6
P/S Multiple
Revenue Growth P/S to Growth
KR
D
DND PharmaTech Inc
KOSDAQ:347850
Average P/S: 3 063 046.4
479.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
33 690 872.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.4
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
5.4
3%
1.8
US
Gilead Sciences Inc
NASDAQ:GILD
6.1
5%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.9
11%
0.9
US
E
Epizyme Inc
F:EPE
2 091
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
10%
0.5
AU
CSL Ltd
ASX:CSL
3.1
4%
0.8
US
S
Seagen Inc
F:SGT
20.1
30%
0.7
NL
argenx SE
XBRU:ARGX
10.6
27%
0.4
P/E Multiple
Earnings Growth PEG
KR
D
DND PharmaTech Inc
KOSDAQ:347850
Average P/E: 36.5
Negative Multiple: -115.3
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 127.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
92.8
97%
1
US
Amgen Inc
NASDAQ:AMGN
25.6
20%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
21.2
16%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.2
16%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -533.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
13%
1.3
AU
CSL Ltd
ASX:CSL
34.5
10%
3.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.8 N/A N/A
NL
argenx SE
XBRU:ARGX
34
32%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
KR
D
DND PharmaTech Inc
KOSDAQ:347850
Average EV/EBITDA: 18.2
Negative Multiple: -116.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 446.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
12%
1.3
US
Amgen Inc
NASDAQ:AMGN
14.7
10%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
9%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -581 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.9
18%
0.7
AU
CSL Ltd
ASX:CSL
11.4
7%
1.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.6 N/A N/A
NL
argenx SE
XBRU:ARGX
36.8
50%
0.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
KR
D
DND PharmaTech Inc
KOSDAQ:347850
Average EV/EBIT: 20.4
Negative Multiple: -100.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 227.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
21.2
24%
0.9
US
Amgen Inc
NASDAQ:AMGN
14.7
3%
4.9
US
Gilead Sciences Inc
NASDAQ:GILD
16.3
13%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.7
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -565.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.8
23%
0.6
AU
CSL Ltd
ASX:CSL
14.3
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.1 N/A N/A
NL
argenx SE
XBRU:ARGX
37.6
56%
0.7
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett